Predictors of frontline doublet or triplet regimen initiation in transplant-ineligible newly diagnosed multiple myeloma.

Journal: Future science OA
Published Date: Jul 12, 2025

Abstract

AIMS: To identify predictors for initiation of frontline doublet versus triplet therapy for transplant-ineligible newly diagnosed multiple myeloma.

Authors

  • Matthew J Pianko
    Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA.
  • Niodita Gupta-Werner
    Johnson and Johnson Innovative Medicine, US Medical Affairs, Horsham, PA, USA.
  • Bruno Emond
    Analysis Group, Inc, Montréal, QC, Canada.
  • Patrick Lefebvre
    Analysis Group, Inc., Montréal, QC, Canada.
  • Marie-Hélène Lafeuille
    Analysis Group, Inc., Montréal, QC, Canada.
  • Annelore Cortoos
    Johnson and Johnson Innovative Medicine, US Medical Affairs, Horsham, PA, USA.
  • Shuchita Kaila
    Johnson and Johnson Innovative Medicine, US Medical Affairs, Horsham, PA, USA.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals